Q1 2025 results - Tuesday, April 29, 2025
Media release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)
Interim financial report (PDF 0.3 MB)
Quarterly impact and sustainability update (ESG):
Novartis Q1 2025 impact and sustainability update (PDF 0.9 MB)
Download the interactive presentation (PDF 3.7 MB)
Download the podcast (MP3 32 MB)
Download 2025 epidemiology data (PDF 2.0 MB)
Key figures1 | Q1 2025 (USD m) | Q1 2024 (USD m) | % change (USD/cc) |
---|---|---|---|
Net sales | 13,233 | 11,829 | 12 (cc: 15) |
Operating income | 4,663 | 3,373 | 38 (cc: 44) |
Net income | 3,609 | 2,688 | 34 (cc: 37) |
EPS (USD) | 1.83 | 1.31 | 40 (cc: 42) |
Free cash flow | 3,391 | 2,038 | 66 |
Core | |||
Operating income | 5,575 | 4,537 | 23 (cc: 27) |
Net income | 4,482 | 3,681 | 22 (cc: 26) |
EPS (USD) | 2.28 | 1.80 | 27 (cc: 31) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 31 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.